In order to expand their facilities to support leading medical treatments, Genzyme Corporation selected Gilbane to provide construction management services for the 59,000ft² expansion of a Cell Culture Manufacturing Facility and supporting laboratory and office space.
The facility expansion required a multi-phased approach including the demolition of an existing building and construction of a new addition to house production facilities that meet cGMP clean room standards. All demolition work took place in a fully operational facility. Extremely close coordination with the owner and detailed logistics were required to ensure the operational facility was not impacted by construction activities. This new facility houses production of Fabrazyme, the only approved treatment option for patients suffering from Fabry disease.